Qiagen NV

Type: Company
Name: Qiagen NV
Nationality: Netherlands
Web Address: http://www.qiagen.com/
Fact Sheet: Fact Sheet for Qiagen NV
First reported 10 hours ago - Updated 5 hours ago - 2 reports

Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents

Qiagen ($QGEN) aims to develop new tests to target blood cancer patients who would benefit most from a particular treatment that hits a specific gene mutation. The plan could lead to new companion diagnostic tests for related drugs now under developm ... [Published Fierce BioMarkers - 5 hours ago]
First reported Jul 24 2014 - Updated 7 hours ago - 2 reports

Qiagen Adds Cancer Biomarkers to Personalized Healthcare Pipeline

Qiagen has acquired an exclusive global license from the University of Tokyo for the biomarker SF3B1. The company said it sees potential for developing companion diagnostics to guide myelodysplastic syndromes (MDS) treatment with new anticancer compounds ... [Published Genetic Engineering News - 7 hours ago]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Global Molecular Diagnostics Market Report: 2014 Edition – New Report by Koncept Analytics

Vaishali, India, July 24, 2014 --( PR.com )-- Despite having one of the world’s highest penetration rates of contraceptives, the US has been experiencing a rise in prevalence of sexually transmitted diseases (or that of CT/NG and HPV to be precise). ... [Published PR.com Press Releases - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Molecular Diagnostics: Why Joint Ventures and Partnerships are the Keys to Market Success

Home - > IVD - > Postedin IVD by MDDI Staff on July 22, 2014Diagnostics companies are increasingly seeking strategic opportunities to enhance their capabilities in the molecular diagnostics sector and tap into the market’s growth potential.By Bruce ... [Published Medical Device & Diagnostic Industry - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

New Panels Target Cancer-Related Genes

Qiagen, Valencia, Calif, has introduced 14 new GeneRead DNAseq V2 gene panels targeting an extensive range of cancer-related genes or gene regions. Gene panels are an integral part of many next-generation sequencing (NGS) workflows and are used to enrich ... [Published Clinical Lab Products - Jul 22 2014]
Entities: Qiagen NV, Assay, Valencia
First reported Jul 20 2014 - Updated Jul 20 2014 - 1 reports

QIAGEN's artus GBS QS-RGQ Kit, Developed with IMDx Obtains CE Marking

The artus GBS QS-RGQ Kit, which is intended as an aid in detecting Group B Streptococcus (GBS) colonization in pregnant women, has obtained CE-marking for use with QIAsymphony SP/AS and Rotor-Gene Q instruments. GBS can be responsible for life-threatening ... [Published Advance for Administrators of the Laboratory - Jul 20 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

US Federal Business Opportunity: Department of Justice: QIAGEN QIAcube & EZ1 Advance XL

Agency: Department of JusticeOffice: Federal Bureau of Investigation Location: Procurement SectionDate you need to respond by: 23-July-2014Solicitation Number: PR-0010897 Naics code: 334516 Computer and Electronic Product ManufacturingDescription:Notice ... [Published ITbriefing - Jul 19 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 3 reports

QIAGEN advances leadership in pre-analytical solutions for next-generation sequencing (NGS) with launch of 14 new cancer gene panels

First reported Jul 14 2014 - Updated Jul 15 2014 - 2 reports

Qiagen (QGEN) Trading Near $24.65 Support Level

Qiagen NV (QGEN) presents a trading opportunity that offers a 7.76% return in just 130 days.A covered call on Qiagen at the $25.00 level expiring on Nov. '14 offers an assigned return rate of 7.76% or 21.78% annualized. This trade offers 7.57% downside ... [Published MarketIntelligenceCenter.com - Jul 15 2014]
Entities: Qiagen NV
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

Is Sigma-Aldrich in the market for the next tax-inversion target?

Netherlands-based Qiagen could be the next — and one of the most expensive — takeover target in the health-care industry, and Sigma-Aldrich has been tagged as a potential buyer.Qiagen's Dutch domicile could make it an attractive tax-inversion target, ... [Published St Louis Business Journal - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Qiagen N.V. (QGEN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Summary:Qiagen reported first-quarter 2014 results with adjusted EPS of $0.22, which was up 10.0% year over year but was in line with the Zacks Consensus Estimate. Adjusted net sales were up 5.0% at $317.4 million, in line with the Zacks Consensus Estimate. ... [Published Zacks.com - Jul 08 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 3 reports

11.9% Return Seen to Date on SmarTrend QIAGEN Call (QGEN)

Written on Mon, 06/30/2014 - 11:27amBy Shiri GuptaSmarTrend identified an Uptrend for QIAGEN ( NASDAQ:QGEN ) on April 29th, 2014 at $21.73. In approximately 2 months, QIAGEN has returned 11.90% as of today's recent price of $24.31.In the past 52 weeks, ... [Published Comtex SmarTrend - Jun 30 2014]

Quotes

The "Human Identification Market by Technology (Next Generation Sequencing, Rapid DNA Analysis, Capillary Electrophoresis, PCR), Application (Forensics, Paternity Testing), DNA Amplification, Quantification, Extraction, Services, & Software - Forecast to 2018" , provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Human...
...the organization from Farella Braun + Martel in San Francisco, where he focused on copyright and other intellectual property litigation matters. "With the ongoing net neutrality debate, and significant copyright reform on the horizon, it's an incredibly important and exciting time for technology policy. Engine is a leading startup voice on these issues, and I'm thrilled to be able to contribute to Engine's work ensuring that startups have the support they need to continue driving the economy,” said Engstrom."
"I truly believe that we are in a golden age for diagnostics and with ever increasing health demands from a growing and ageing population, diagnostics can provide a key role in helping contain costs and at the same time improve overall patient care through disease prevention, early intervention, patient monitoring and ensuring the right patients get the right medicine at the right time."
"By delivering high-quality solutions for sample processing, assay design and data analysis and interpretation, QIAGEN is addressing the key bottlenecks of current sequencing workflows, making NGS technology more effective, robust and scalable. We today offer the largest collection of gene panels in the market and are rapidly expanding our portfolio of high-utility solutions that help labs create fast and integrated workflows" said Peer M Schatz, CEO of QIAGEN

More Content

All (398) | News (236) | Reports (1) | Blogs (82) | Audio/Video (0) | Fact Sheets (3) | Press Releases (76)
sort by: Date | Relevance
Qiagen sees blood cancer biomarker Dx potential... [Published Fierce BioMarkers - 5 hours ago]
Qiagen Adds Cancer Biomarkers to Personalized H... [Published Genetic Engineering News - 7 hours ago]
Qiagen gains license for potential blood cancer... [Published BioPortfolio - 10 hours ago]
QIAGEN Adds Promising Genomic Biomarkers for As... [Published PR Newswire: Health - Jul 24 2014]
Screening Tool Simplifies Serological Diagnosis... [Published Lab Medica - Jul 24 2014]
New Market Report: CytoCore, Inc. (CYOE) - Prod... [Published SBWire - Jul 24 2014]
Qiagen (QGEN) Showing Bullish Technicals With R... [Published MarketIntelligenceCenter.com - Jul 24 2014]
Global Molecular Diagnostics Market Report: 201... [Published PR.com Press Releases - Jul 24 2014]
QIAGEN Has Returned 15.2% Since SmarTrend Recom... [Published Comtex SmarTrend - Jul 24 2014]
QIAGEN Has Returned 15.2% Since SmarTrend Recom... [Published Individual.com - Jul 23 2014]
Global IVD Market 2014-2018 [Published Medical Design Technology - Jul 23 2014]
eGym partners with Highland Capital Partners Eu... [Published High-Tech Gründerfonds GmbH - Jul 23 2014]
United States Market for In Vitro Diagnostic Te... [Published Individual.com - Jul 23 2014]
Global Market for Biomarkers Report: Cancer, Ca... [Published Individual.com - Jul 23 2014]
Molecular Diagnostics Global Industry Growth an... [Published MyNewsDesk - Jul 23 2014]
Molecular Diagnostics: Why Joint Ventures and P... [Published Medical Device & Diagnostic Industry - Jul 23 2014]
BUENA VISTA REGIONAL MEDICAL CENTER DISBURSEMENTS [Published Storm Lake Pilot Tribune - Jul 22 2014]
Global Molecular Diagnostics Market Report 2014... [Published The CW44 Tampa Bay - Jul 22 2014]
Global Molecular Diagnostics Market Report 2014... [Published MyNewsDesk - Jul 22 2014]
Global IVD Market 2014-2018: Key Vendors are Ab... [Published Tamar Securities - Jul 22 2014]
New Panels Target Cancer-Related Genes [Published Clinical Lab Products - Jul 22 2014]
Shareholders Support Management Proposals At A... [Published BioSpace - Jul 21 2014]
Global Transcriptomics Market 2014-2018 with Ab... [Published Individual.com - Jul 21 2014]
Potential Qiagen (QGEN) Trade Has 7.15% Downsid... [Published MarketIntelligenceCenter.com - Jul 21 2014]
SYGNIS : Shareholders support Management propos... [Published 4 Traders - Jul 21 2014]
Human Identification Market by Technology, Appl... [Published Individual.com - Jul 21 2014]
QIAGEN's artus GBS QS-RGQ Kit, Developed with I... [Published Advance for Administrators of the Laboratory - Jul 20 2014]
US Federal Business Opportunity: Department of ... [Published ITbriefing - Jul 19 2014]
Dynamically-Driven Enhancement of the Catalytic... [Published Plosone.org - Jul 19 2014]
Hottest Healthcare Stocks Now – IMGN MNKD CNMD ... [Published InvestorPlace.com - Jul 19 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
QIAGEN Adds Promising Genomic Biomarkers for As... [Published PR Newswire: Health - Jul 24 2014]
HILDEN, Germany, and MARSEILLE, France, July 24, 2014 /PRNewswire/ --Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers ...
Qiagen (QGEN) Showing Bullish Technicals With R... [Published MarketIntelligenceCenter.com - Jul 24 2014]
Qiagen NV (QGEN) traded between $24.72 and $25.04 before closing at $25.03 Wednesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Nov. '14 $25.00 covered call for a net debit of ...
Global Molecular Diagnostics Market Report: 201... [Published PR.com Press Releases - Jul 24 2014]
Vaishali, India, July 24, 2014 --( PR.com )-- Despite having one of the world’s highest penetration rates of contraceptives, the US has been experiencing a rise in prevalence of sexually transmitted diseases (or that of CT/NG and HPV to be precise). ...
Potential Qiagen (QGEN) Trade Has 7.15% Downsid... [Published MarketIntelligenceCenter.com - Jul 21 2014]
For a hedged play on Qiagen NV (QGEN), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Nov. '14 $25.00 covered call for a net debit in the $23.38 area. That is also the break-even stock price for the covered call. This trade ...
Qiagen (QGEN) Showing Bullish Technicals With R... [Published MarketIntelligenceCenter.com - Jul 18 2014]
After Thursday’s trading in Qiagen NV (QGEN) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 4.02% or 11.56% (for comparison purposes only), while providing 11.46% downside protection. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Updates, Recognitions and Social Medi... [Published Financial Services - Jul 18 2014]
DGAP-PVR: QIAGEN N.V.: Release according to Art... [Published GlobeNewswire: Advertising News - Jun 11 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
DGAP-CMS: QIAGEN N.V.: Release of a capital mar... [Published GlobeNewswire: Acquisitions News - Jun 02 2014]
QIAGEN and Lilly Collaborate to Co-Develop Comp... [Published Financial Services - May 30 2014]
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.